



US011203565B2

(12) **United States Patent**
Asano et al.

(10) **Patent No.:** **US 11,203,565 B2**
(45) **Date of Patent:** **Dec. 21, 2021**

(54) **ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED**

(2013.01); *C07C 65/40* (2013.01); *C07C 229/16* (2013.01); *C07C 229/56* (2013.01); *C07D 209/08* (2013.01); *C07D 209/86* (2013.01); *C07D 265/38* (2013.01); *C07D 307/68* (2013.01)

(71) Applicants: **Hiroshima University**, Higashihiroshima (JP); **Tokyo University of Pharmacy & Life Sciences**, Hachioji (JP); **The University of Tokyo**, Tokyo (JP)

(58) **Field of Classification Search**
None
See application file for complete search history.

(72) Inventors: **Tomoichiro Asano**, Hiroshima (JP); **Yusuke Nakatsu**, Hiroshima (JP); **Hisanaka Ito**, Hachioji (JP); **Takayoshi Okabe**, Tokyo (JP)

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

(73) Assignees: **Hiroshima University**, Hiroshima (JP); **Tokyo University of Pharmacy & Life Sciences**, Tokyo (JP); **The University of Tokyo**, Tokyo (JP)

CA	2517281	10/2004
EP	1603926	12/2005
JP	2006-523669	10/2006
WO	WO 2004/087720	10/2004

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 29 days.

Yu et al., Function of PIN1 in Cancer Development and Its Inhibitors as Cancer Therapeutics. *Frontiers in Cell and Developmental Biology*, 2020, 8, p. 1-12.*

(21) Appl. No.: **16/464,034**

(Continued)

(22) PCT Filed: **Nov. 29, 2017**

Primary Examiner — Po-Chih Chen

(86) PCT No.: **PCT/JP2017/042804**
§ 371 (c)(1),
(2) Date: **May 24, 2019**

(74) *Attorney, Agent, or Firm* — William C. Schrot;
Jeffrey I. Auerbach; AuerbachSchrot LLC

(87) PCT Pub. No.: **WO2018/101329**
PCT Pub. Date: **Jun. 7, 2018**

(57) **ABSTRACT**

(65) **Prior Publication Data**
US 2019/0382330 A1 Dec. 19, 2019


An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

(30) **Foreign Application Priority Data**

Nov. 29, 2016 (JP) JP2016-231875

(51) **Int. Cl.**
C07C 65/30 (2006.01)
A61P 35/00 (2006.01)
A61P 1/16 (2006.01)
A61P 1/04 (2006.01)
A61K 9/00 (2006.01)
C07C 65/40 (2006.01)
C07C 62/36 (2006.01)
C07D 307/68 (2006.01)
C07D 209/86 (2006.01)
C07D 209/08 (2006.01)
C07C 229/56 (2006.01)
C07C 229/16 (2006.01)
C07C 59/74 (2006.01)
C07D 265/38 (2006.01)

(52) **U.S. Cl.**
CPC *C07C 65/30* (2013.01); *A61K 9/0019* (2013.01); *A61K 9/0053* (2013.01); *A61P 1/04* (2018.01); *A61P 1/16* (2018.01); *A61P 35/00* (2018.01); *C07C 59/74* (2013.01); *C07C 62/36*



18 Claims, 8 Drawing Sheets
Specification includes a Sequence Listing.

(56)

References Cited

OTHER PUBLICATIONS

Schafer, S., Kolkhof, P. Failure is an option: learning from unsuccessful proof-of-concept trials. *Drug Discovery Today*. Nov. 2008, 13, 913-916.*

Horig, H., Pullman, W. From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. *Journal of Translational Medicine*. Dec. 2004, 2, 44.*

Chemical Abstract Registry No. 95166-12-4, indexed in the Registry File on STN CAS Online Mar. 9, 1985.*

Grant & Hackh's Chemical Dictionary (5th Ed. 1987) at p. 148.*

Diaz-Alvarez, A.E., et al. (2014) "Access to Optically Pure beta-Hydroxy Esters via Non-Enzymatic Kinetic Resolution by a Planar-Chiral DMAP Catalyst," *Molecules* 19(9): 14273-14291.

International Search Report PCT/JP2017/042804 (WO 2018/101329) (dated 2018) (5 pages).

Potter, A.J., et al. (2010) "Structure-guided Design of α -amino Acid-derived Pin1 Inhibitors," *Bioorg. & Medicinal Chem. Lett.* 20(2):586-590.

Tan, F., et al. (2016) "Asymmetric Catalytic Insertion of α -Diazo Carbonyl Compounds into O—H Bonds of Carboxylic Acids," *ACS Catalysis* 6(10):6930-6934.

Written Opinion of the International Searching Authority PCT/JP2017/042804 (WO 2018/101329) (dated 2018) (5 pages).

Chan, A., et al. (2006) "Hydroacylation of Activated Ketones Catalyzed by N-Heterocyclic Carbenes," *J. Am. Chem. Soc.* 128(14):4558-4559.

European Search Report EP 17875374.5 (dated Aug. 25, 2020) (8 pages).

Georgiev, A.G., et al. (1964) "The production of β -hydroxy- β -naphthalpropionic esters by means of Reformatsky's reaction," *Dokl. Akad. Nauk SSSR* 154:132-135.

* cited by examiner